245 related articles for article (PubMed ID: 25848766)
21. APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival.
Yang J; Yang D; Cogdell D; Du X; Li H; Pang Y; Sun Y; Hu L; Sun B; Trent J; Chen K; Zhang W
Technol Cancer Res Treat; 2010 Apr; 9(2):161-9. PubMed ID: 20218738
[TBL] [Abstract][Full Text] [Related]
22. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays.
Squire JA; Pei J; Marrano P; Beheshti B; Bayani J; Lim G; Moldovan L; Zielenska M
Genes Chromosomes Cancer; 2003 Nov; 38(3):215-25. PubMed ID: 14506695
[TBL] [Abstract][Full Text] [Related]
23. Germ-line genetic variation of TP53 in osteosarcoma.
Savage SA; Burdett L; Troisi R; Douglass C; Hoover RN; Chanock SJ;
Pediatr Blood Cancer; 2007 Jul; 49(1):28-33. PubMed ID: 17096406
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.
Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q
Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA HOTTIP is up-regulated and associated with poor prognosis in patients with osteosarcoma.
Li F; Cao L; Hang D; Wang F; Wang Q
Int J Clin Exp Pathol; 2015; 8(9):11414-20. PubMed ID: 26617868
[TBL] [Abstract][Full Text] [Related]
26. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
27. Identification of Key Gene Modules in Human Osteosarcoma by Co-Expression Analysis Weighted Gene Co-Expression Network Analysis (WGCNA).
Liu X; Hu AX; Zhao JL; Chen FL
J Cell Biochem; 2017 Nov; 118(11):3953-3959. PubMed ID: 28398605
[TBL] [Abstract][Full Text] [Related]
28. Insights on PRAME and osteosarcoma by means of gene expression profiling.
Toledo SR; Zago MA; Oliveira ID; Proto-Siqueira R; Okamoto OK; Severino P; Vêncio RZ; Gamba FT; Silva WA; Moreira-Filho CA; Torre CA; Alves MT; Garcia-Filho RJ; Simpson AJ; Petrilli AS
J Orthop Sci; 2011 Jul; 16(4):458-66. PubMed ID: 21691740
[TBL] [Abstract][Full Text] [Related]
29. Modeling osteosarcoma progression by measuring the connectivity dynamics using an inference of multiple differential modules algorithm.
Liu B; Zhang Z; Dai EN; Tian JX; Xin JZ; Xu L
Mol Med Rep; 2017 Aug; 16(2):1047-1054. PubMed ID: 28586048
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma.
Man TK; Lu XY; Jaeweon K; Perlaky L; Harris CP; Shah S; Ladanyi M; Gorlick R; Lau CC; Rao PH
BMC Cancer; 2004 Aug; 4():45. PubMed ID: 15298715
[TBL] [Abstract][Full Text] [Related]
31. XB130 expression in human osteosarcoma: a clinical and experimental study.
Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
[TBL] [Abstract][Full Text] [Related]
32. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
[TBL] [Abstract][Full Text] [Related]
33. Bioinformatics integrated analysis to investigate candidate biomarkers and associated metabolites in osteosarcoma.
Wang J; Gong M; Xiong Z; Zhao Y; Xing D
J Orthop Surg Res; 2021 Jul; 16(1):432. PubMed ID: 34225733
[TBL] [Abstract][Full Text] [Related]
34. The breakage-fusion-bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma.
Selvarajah S; Yoshimoto M; Park PC; Maire G; Paderova J; Bayani J; Lim G; Al-Romaih K; Squire JA; Zielenska M
Chromosoma; 2006 Dec; 115(6):459-67. PubMed ID: 16897100
[TBL] [Abstract][Full Text] [Related]
35. Transcriptome Analysis Identifies Novel Prognostic Genes in Osteosarcoma.
Chen J; Guo X; Zeng G; Liu J; Zhao B
Comput Math Methods Med; 2020; 2020():8081973. PubMed ID: 33082842
[TBL] [Abstract][Full Text] [Related]
36. Genomics and the Immune Landscape of Osteosarcoma.
Wu CC; Livingston JA
Adv Exp Med Biol; 2020; 1258():21-36. PubMed ID: 32767232
[TBL] [Abstract][Full Text] [Related]
37. Identification of key gene modules for human osteosarcoma by co-expression analysis.
Zhang J; Lan Q; Lin J
World J Surg Oncol; 2018 May; 16(1):89. PubMed ID: 29720180
[TBL] [Abstract][Full Text] [Related]
38. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
39. Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma.
Scott MC; Temiz NA; Sarver AE; LaRue RS; Rathe SK; Varshney J; Wolf NK; Moriarity BS; O'Brien TD; Spector LG; Largaespada DA; Modiano JF; Subramanian S; Sarver AL
Cancer Res; 2018 Jan; 78(2):326-337. PubMed ID: 29066513
[TBL] [Abstract][Full Text] [Related]
40. Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma.
Negri GL; Grande BM; Delaidelli A; El-Naggar A; Cochrane D; Lau CC; Triche TJ; Moore RA; Jones SJ; Montpetit A; Marra MA; Malkin D; Morin RD; Sorensen PH
J Pathol; 2019 Nov; 249(3):319-331. PubMed ID: 31236944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
